Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 8/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291246 | 0.91 | LMNA (0.41) | ALPLNPC1TSHRALDH1A1KMT2A | |
| SCHEMBL6291261 | 0.91 | ALPL (0.43) | ALPLMAPK1NPC1TSHRALDH1A1 | |
| SCHEMBL6294290 | 0.90 | FDPS (0.42) | MAPK1NPC1TSHRALDH1A1MAPT | |
| SCHEMBL7088256 | 0.89 | ALPL (0.44) | ALPLMAPK1NPC1TSHRALDH1A1 | |
| SCHEMBL6293951 | 0.84 | LMNA (0.44) | NPC1TSHRALDH1A1KMT2AHSP90AA1 | |
| SCHEMBL6291234 | 0.83 | LMNA (0.39) | ALPLNPC1TSHRALDH1A1MEN1 | |
| SCHEMBL6291102 | 0.82 | FDPS (0.42) | ALPLMAPK1NPC1TSHRALDH1A1 | |
| SCHEMBL6291250 | 0.79 | KDM4E (0.46) | MAPK1NPC1TSHRALDH1A1MEN1 | |
| SCHEMBL6290586 | 0.77 | LMNA (0.42) | ALPLMAPK1NPC1TSHRALDH1A1 | |
| SCHEMBL6308462 | 0.75 | ALPL (0.45) | ALPLMAPK1NPC1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872711-B2 | β-substituted β-aminoethyl phosphonate derivatives | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2005-03-29 | — | — | US | claimed |
| EP-1330463-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-07-30 | — | — | EP | claimed |
| US-20020111488-A1 | Beta-substitued beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002034756-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-05-02 | — | — | WO | claimed |
| US-6872711-B2 | β-substituted β-aminoethyl phosphonate derivatives | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2005-03-29 | — | — | US | disclosed |
| EP-1330463-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-07-30 | — | — | EP | disclosed |
| US-20020111488-A1 | Beta-substitued beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002034756-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111488-A1 | Beta-substitued beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | ALPL 569/4885MAPK1 2997/4885NPC1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.